Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Leuk Lymphoma
Päätekijät: Hampel, Paul J., Ding, Wei, Call, Timothy G., Rabe, Kari G., Kenderian, Saad S., Witzig, Thomas E., Muchtar, Eli, Leis, Jose F., Chanan-Khan, Asher A., Koehler, Amber B., Fonder, Amie L., Schwager, Susan M., Slager, Susan L., Shanafelt, Tait D., Kay, Neil E., Parikh, Sameer A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6813846/
https://ncbi.nlm.nih.gov/pubmed/31014142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1602268
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia